Search

Displaying results 761 - 770 of 4339 in total
  1. Drug

    Human C1-esterase inhibitor

    go.drugbank.com/drugs/DB06404
    ApprovedInvestigational

    The disease is characterized by acute attacks of painful, and in some cases, fatal swelling of several soft tissues or edema, which may last up to five days when untreated.[L16586, L16606] … [L16586, L16606] This drug is indicated for prophylaxis and treatment of Hereditary Angioedema (HAE), a human genetic disorder caused by a shortage of C1 inhibitor activity that results in an overreaction

  2. Drug

    Calcium chloride

    go.drugbank.com/drugs/DB01164
    ApprovedInvestigational

    It can be produced directly from limestone, but large amounts are also produced as a by-product of the Solvay process. Because of its hygroscopic nature, it must be kept in tightly-sealed containers.

  3. Drug

    Lanadelumab

    go.drugbank.com/drugs/DB14597
    ApprovedInvestigational

    [A38676] Lanadelumab was approved for use in patients with hereditary angioedema by the FDA in August 2018,[L4537] followed by Health Canada in October 2018[L49226] and the EMA in November 2018.

  4. Drug

    Zilucoplan

    go.drugbank.com/drugs/DB15636
    ApprovedInvestigational

    [L48701] It was also later approved by the EMA on December 4, 2023, as an add-on treatment for the same condition.[L49131] In July 2024, it was approved by Health Canada for the same indication.

  5. Drug

    Atenolol

    go.drugbank.com/drugs/DB00335
    ApprovedInvestigational

    Atenolol itself was developed early on in this history by Alvogen Malta under the trade name Tenormin and received FDA approval in September, 1981.

    Mixtures: ATENOCOMP 1A 50MG/12.5MG, ATENOCOMP 1A 50MG/12.5MGProducts: JUVENTAL 50MG, ATENOLOL 50MG
  6. Drug

    Lacosamide

    go.drugbank.com/drugs/DB06218
    ApprovedInvestigational

    [A262681] Lacosamide was first approved by the European Commission in August 2008 and was later approved by the FDA in October 2008. … [A262681] It was granted approval by Health Canada in September 2010.[L49206]

    Products: APILEP® 50MG, BENVIDA 10MG/ML ŞURUP, 200 ML
  7. Drug

    Nadolol

    go.drugbank.com/drugs/DB01203
    ApprovedInvestigational

    Nadolol is a nonselective beta adrenal receptor blocker that is used to lower blood pressure. Nonselective beta adrenal receptor blockers may no longer be first line in the treatment of hypertension as newer generations of beta adrenal r...

    Mixtures: Corzide Tab W Nadolol 80mg, Corzide Tab W Nadolol 40mgProducts: Corgard Tab 80mg, Corgard Tab 40mg
  8. Drug

    Somapacitan

    go.drugbank.com/drugs/DB15093
    ApprovedInvestigational

    [A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily.

    Products: SOGROYA® 10MG/1.5ML
  9. Drug

    Onasemnogene abeparvovec

    go.drugbank.com/drugs/DB15528
    ApprovedInvestigational

    [Nusinersen] is another gene therapy that is currently approved by the FDA for the treatment of SMA in pediatric and adult patients. … Developed by AveXis, a Novartis company,[A187253] onasemnogene abeparvovec is commonly marketed as Zolgensma®, which is available as a single-dose intravenous infusion.

  10. Drug

    Cloxazolam

    go.drugbank.com/drugs/DB01553
    Experimental

    It is marketed in the Argentina, Australia, Portugal, Belgium, Switzerland, Luxembourg, Germany, Taiwan and Japan -- mainly for anti-anxiety. … As well, it has also been studied in Japan in doses of 15-30mg/day as an adjunct in the treatment of intractable epilepsy, for which it has demonstrated effectiveness.